Success Metrics

Clinical Success Rate
40.0%

Based on 4 completed trials

Completion Rate
40%(4/10)
Active Trials
1(5%)
Results Posted
150%(6 trials)
Terminated
6(29%)

Phase Distribution

Ph phase_1
1
5%
Ph phase_2
8
38%
Ph phase_3
3
14%
Ph phase_4
3
14%
Ph early_phase_1
3
14%
Ph not_applicable
2
10%

Phase Distribution

4

Early Stage

8

Mid Stage

6

Late Stage

Phase Distribution20 total trials
Early Phase 1First-in-human
3(15.0%)
Phase 1Safety & dosage
1(5.0%)
Phase 2Efficacy & side effects
8(40.0%)
Phase 3Large-scale testing
3(15.0%)
Phase 4Post-market surveillance
3(15.0%)
N/ANon-phased studies
2(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

30.8%

4 of 13 finished

Non-Completion Rate

69.2%

9 ended early

Currently Active

1

trials recruiting

Total Trials

21

all time

Status Distribution
Active(2)
Completed(4)
Terminated(9)
Other(6)

Detailed Status

Terminated6
Completed4
unknown4
Withdrawn3
Suspended2
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
21
Active
1
Success Rate
40.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (15.0%)
Phase 11 (5.0%)
Phase 28 (40.0%)
Phase 33 (15.0%)
Phase 43 (15.0%)
N/A2 (10.0%)

Trials by Status

withdrawn314%
enrolling_by_invitation15%
completed419%
suspended210%
unknown419%
recruiting15%
terminated629%

Recent Activity

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT04911816Phase 1

Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma

Recruiting
NCT02615938Phase 2

Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)

Terminated
NCT04007562

Acute Rhabdomyolysis and Muscle Pain Associated With Mutations in the LPIN1 Gene - A Retrospective Study Describing the Safety and Efficacy of Hydroxychloroquine Sulfate Given on a Compassionate Basis to Patients Suffering From Lipin-1 Deficiency

Withdrawn
NCT04386057Phase 2

LY3214996 +/- HCQ in Pancreatic Cancer

Completed
NCT06519617Phase 2

Study on Optimization and Evaluation of Integrated Chinese and Western Medicine for pSS Glandular Damage

Enrolling By Invitation
NCT04341727Phase 3

Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection

Terminated
NCT04336332Phase 2

Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19

Terminated
NCT04329572Early Phase 1

Efficacy and Safety of Hydroxychloroquine and Azithromycin for Patients With Moderate to Severe COVID-19

Suspended
NCT04348474Early Phase 1

Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19

Suspended
NCT04354428Phase 2

Treatment for COVID-19 in High-Risk Adult Outpatients

Terminated
NCT04328961Phase 2

Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

Completed
NCT04380818Not Applicable

Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19

Unknown
NCT04340349Early Phase 1

Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals

Unknown
NCT04342221Phase 3

Hydroxychloroquine for COVID-19

Terminated
NCT04361461Phase 3

Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)

Withdrawn
NCT04316377Phase 4

Norwegian Coronavirus Disease 2019 Study

Unknown
NCT04371926Not Applicable

Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk

Withdrawn
NCT04307693Phase 2

Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)

Terminated
NCT02942381Phase 2

A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy

Completed
NCT02765594Phase 4

Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
21